Opinion|Videos|July 17, 2024

Biomarkers: Impact on Treatment Choices and Future Expectations

Author(s)Matthew T. Campbell, MD, MS, Rana R. McKay, MD

The key opinion leaders share their strategies for selecting systemic therapy, comparing immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) approaches, for previously untreated patients with advanced renal cell carcinoma.

Episodes in this series

2 KOLs are featured in this program.

EP. 1 Current treatment options for ccRCC based on patient and disease factors

2 KOLs are featured in this program.

EP. 2 CheckMate-214: Long-term follow-up data

2 KOLs are featured in this program.

EP. 3 Review of CheckMate-214: Long-term follow-up in favorable risk subgroup

2 KOLs are featured in this program.

EP. 4 Review of CLEAR and CheckMate-9ER: Four-Year and 55 Month Follow-Up Data

2 KOLs are featured in this program.

EP. 5 Review of KEYNOTE-426: Five-year Follow-up Data

2 KOLs are featured in this program.

EP. 6 Discontinuation or Continuation of IO Therapy – IO/IO vs. IO/TKI Regimens

2 KOLs are featured in this program.

EP. 7 Treatment-free survival in IO/TKI

2 KOLs are featured in this program.

EP. 8 Biomarkers: Impact on Treatment Choices and Future Expectations

2 KOLs are featured in this program.

EP. 9 Management of Adverse Events – IO/IO and IO/TKI

2 KOLs are featured in this program.

EP. 10 New formulations for current therapies – SC vs. IV

2 KOLs are featured in this program.

EP. 11 Novel Agents/Combinations for aRCC

Dr McKay and Campbell: Please discuss your treatment approach to systemic therapy (IO/IO vs. IO/TKI) for treatment-naïve patients with advanced RCC.
- How do the most recent data updates for CM-214, CLEAR, KN-426, and CM-9ER impact your treatment decisions?
- Please discuss the importance of biomarkers in determining appropriate treatment options.

CLEAR – biomarker analysis (Choueiri, TK, et al. 2024 ASCO Annual Meeting. Abstract 4504).
CheckMate -214 – biomarker analysis (Matar, S, et al 2024 ASCO Annual Meeting. Abstract 4536).
Keynote-426 – biomarker analysis (Rini BI, et al. 2024 ASCO Annual Meeting. Abstract 4505).

Do you have a “go-to” treatment?
- How do you factor OS, PFS, and DOR into your decision-making?
Does it differ for those with intermediate/poor risk vs. favorable risk disease?
If so, what patient-specific variables would cause you to re-evaluate your treatment choice(s)?
- Age? Tumor burden? Kidney function? Performance status? Chronic comorbidities?

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Considering the Role of Tivozanib After Prior ICI-Based Therapy in RCC

October 16th, 2026

Considering the Role of Tivozanib After Prior ICI-Based Therapy in RCC

Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.

How Disease Burden Shapes First-Line RCC Treatment Selection

October 13th, 2026

How Disease Burden Shapes First-Line RCC Treatment Selection

Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.

Heng on Managing Toxicity and Sequencing With Belzutifan/Lenvatinib in RCC

October 8th, 2026

Heng on Managing Toxicity and Sequencing With Belzutifan/Lenvatinib in RCC

Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

2026 AACR Report Highlights Advances and New Directions in Cancer Treatment

Amivantamab vs. Emerging EGFR Bispecifics in HNSCC

ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types

Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer

Dr Beck on the Practical Realities of Subcutaneous Oncology Drug Delivery